News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs30-Jan-2025
TOP HEADLINES
Setback for Inhibikase Parkinson’s therapy
Developer now plans to focus on its other therapeutic candidate for treatment of pulmonary arterial hypertension... Read more
Atalanta Therapeutics raises $97 million to advance RNAi therapies for CNS disorders
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease... Read more
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment... Read more
Akero Therapeutics succeeds with MASH liver treatment at phase 2
... Read more
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, designed to treat amyotrophic lateral sclerosis (ALS), after the FDA lifted its clinical hold on the trial.... Read more
Nanobiotix’s radiotherapy-activated nanoparticle cancer candidate enters Phase 2
The clinical trial will evaluate the therapy for Stage 3 unresectable non-small cell lung cancer.... Read more
Neogap Therapeutics move into clinic with personalized cancer immunotherapy
The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few treatment options.... Read more
Umoja raises $100 million to boost its CAR-T cell gene therapy pipeline
The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and autoimmune diseases.... Read more
Hinge Bio raises $30 million to progress B cell lupus therapy
The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate therapies using the same platform.... Read more
Windward Bio launches to develop potential best-in-class antibody against asthma and COPD
The antibody is ready for a Phase 2 trial and will be tested in people with severe asthma.... Read more
View all news headlines for:    Oct     Nov     Dec
EDITOR'S CHOICE
Viralgen and Axovia collaborate to manufacture gene therapy for rare disease vision loss
The gene therapy aims to stop retinal dystrophy in people with Bardet-Biedl Syndrome.... Read more
GSK and Muna Therapeutics partner to develop new treatments for Alzheimer’s
The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to identify and validate new drug targets for neurodegenerative diseases.... Read more
Cell and gene therapy access model launches in US
The sickle cell gene therapies developed by Bluebird Bio and Vertex will be the first to be offered under the new scheme.... Read more
PREVIOUS HEADLINES
Biosimilars in the UK: Insights from Biocon Biologics
Data integration and its role in advancing personalized medicine
Women in Science: ‘Stay curious, be persistent, and embrace the power of mentorship’, says Kerry Love of Sunflower Therapeutics
Women in Science: Laura Crowell on overcoming imposter syndrome
Women in Science: Dr Jennifer Bradford on following your passions – even if your dream job doesn’t exist yet
Free Newsletters for Pharmaceuticals & Science
 Explore more of our newsletters
SIGN UP
To continue to receive this newsletter in your inbox, please whitelist our newsletters.
Unsubscribe | Privacy policy | Contact the Editor | Advertise with us
© William Reed Ltd 2025. All Rights Reserved.
Registered Office: Broadfield Park, Crawley RH11 9RT.
Registered in England No. 2883992. VAT No. 644 3073 52.
www.william-reed.com